Frontline Pembrolizumab for PD-L1–Positive Gastric Cancer: Kohei Shitara, MD

Gastric or gastroesophageal junction (G/GEJ) cancer constitutes the third leading cause of cancer death worldwide, and more therapeutic options are needed. In results from the phase 3 KEYNOTE-062 study, published last week in JAMA Oncology, Kohei Shitara, MD, and colleagues reported that in patients with previously untreated G/GEJ cancer with a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater, pembrolizumab, alone or in combination with chemotherapy, was nonin...
Continue reading

PD-L1–Positive Gastric Cancer: Frontline Pembrolizumab Noninferior to Chemotherapy

Data from the phase 3 KEYNOTE-062 trial have revealed that in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer with a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater, first-line pembrolizumab, alone or in combination with chemotherapy, is noninferior but not superior to chemotherapy alone. In patients with a PD-L1 CPS of 10 or greater, pembrolizumab monotherapy showed a possible benefit, but one that cannot be considered definitive o...
Continue reading

Eradicating H. Pylori Reduces Gastric Cancer Risk

Being infected with Helicobacter pylori (H. pylori), a bacterium that grows in the stomach, and having a family history of gastric cancer are the two main risk factors for developing gastric cancer. Results from a recent study revealed that treatment to eradicate H. pylori can help reduce gastric cancer risk in those who have the bacterium and a family history of the disease. For the single-center, double-blind, placebo-controlled study, results of which are published in The New England Journal ...
Continue reading

Weight Loss Associated With Lower Survival in Patients With Gastric Cancer

Many patients with advanced gastric cancer inevitably lose weight while receiving systemic treatment, with some patients struggling with maintaining adequate nutrition. Researchers set out to investigate the impact of losing weight early on in treatment on patients' survival. For this study, results of which are published in Journal of Clinical Oncology, phase 3 trials involving patients with gastric/gastroesophageal junction (GEJ) cancer receiving ramucirumab were analyzed by the researchers: R...
Continue reading

Ramucirumab/Pembrolizumab in Patients With NSCLC, Gastric Cancer, or Urothelial Carcinoma

A phase 1a/b trial (NCT02443324) reports that ramucirumab in conjunction with pembrolizumab is effective in patients with previously treated advanced non-small cell lung cancer (NSCLC), gastroesophageal cancer, or urothelial carcinomas. Ramucirumab, a monoclonal antibody, blocks vascular endothelial growth factor receptor 2 (VEGFR2), which allows cancer cells to grow and metastasize. Pembrolizumab is also a monoclonal antibody, but it works by blocking programmed cell death protein-1 (PD-1), in ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.